For best viewing of the website please use Mozilla Firefox or Google Chrome.
Citation: Zhi-ying OU, Rong ZHOU, Yun-shao HE. YVDD Mutation of Hepatitis B Virus, a Dominant Lamivudine-Resistant Type in Guangzhou, South China [J].VIROLOGICA SINICA, 2008, 23(3) : 218-225.  http://dx.doi.org/10.1007/s12250-008-2963-6

YVDD Mutation of Hepatitis B Virus, a Dominant Lamivudine-Resistant Type in Guangzhou, South China

  • Corresponding author: Yun-shao HE, gzcentralab@yahoo.com.cn
  • Received Date: 27 March 2008
    Accepted Date: 02 April 2008
    Available online: 01 June 2008

    Fund Project:

  • The epidemiological effects of native and mutated YMDD motif in the HBV genome under the selective pressure of lamivudine were investigated. YMDD wild and mutation motif in HBV genome were detected by flow through reverse dot blots (FT-RDB) with KaiPuTM DNA HybriMax Rapid Hybridization Machine based on the principle of “Flow-through hybridization” and by the traditional Reverse Dot Blot assay. Sera from 1 021 suspected lamivudine-resistant chronic HBV carriers after more than 8 months of lamivudine therapy and the corresponding archived sera were collected and assayed. We found 35.94% were single type infections with 8.03% YMDD, 7.93% YIDD and 19.98% YVDD. It was also found that 64.06% were mixed infections including 1.96% YMDD and YIDD, 51.62% YMDD and YVDD, 1.96% YIDD and YVDD, 8.52% YMDD, YIDD and YVDD. The levels of infections containing YVDD motif reached 82.08%. The pretreatment infectious status were: YMDD single infection was 36.93%; YIDD single infection was 6.07%; YVDD single infection was 17.04%; YMDD and YIDD mixed infection was 0.97%; YMDD and YVDD mixed infection was 33.99%; YIDD and YVDD mixed infection was 0.98%; YMDD, YIDD and YVDD mixed infection was 4.02%. Infections containing YVDD motif were only 56.03%. The 34.32% mutation rate of YMDD motif to YVDD was significantly higher than the 10.97% of YMDD to YIDD (U=10.98, P<0.05), as estimated by Mann-Whitney U-test for non-parametric data. HBV containing YVDD motif might have an evolutionary ascendancy and become the dominant type under the selective pressure of lamivudine.

  • 加载中
    1. Atkins M, Hunt C M, Brown N, et al. 1998. Clinical significance of YMDD mutant hepatitis B virus in large cohort of lamivudine-treated hepatitis B patients. He-patology, 28: A319.

    2. Clarke B, Bloor S. 2002. Molecular genotyping of hepatitis B virus. J Clin Virol, 25 Suppl 3: S41-45.

    3. Dienstag J L, Schiff E R, Wright T L, et al. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med, 341: 1256-1263.
        doi: 10.1056/NEJM199910213411702

    4. Günther S, Li B C, Miska S, et al. 1995. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol, 69: 5437-5444.

    5. Gutfreund K S, Williams M, George R, et al. 2000. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol, 33: 469-475.
        doi: 10.1016/S0168-8278(00)80284-6

    6. Lai C L, Chien R N, Leung N W, et al. 1998. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med, 339: 61-68.
        doi: 10.1056/NEJM199807093390201

    7. Lai C L, Dienstag J, Schiff E, et al. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis, 36: 687-696.
        doi: 10.1086/cid.2003.36.issue-6

    8. Leung N W, Lai C L, Chang T T, et al. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 33: 1527-1532.
        doi: 10.1053/jhep.2001.25084

    9. Locarnini S. 2004. Molecular virology of hepatitis B virus. Semin Liver Dis, 24 Suppl 1: 3-10.

    10. Maynard J E. 1990. Hepatitis B: global importance and need for control. Vaccine, 8 Suppl: S18-20; discussion S21-23.

    11. Moraleda G, Saputelli J, Aldrich C E, et al. 1997. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol, 71: 9392-9399.

    12. Nowak M A, Bonhoeffer S, Hill A M, et al. 1996. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA, 93: 4398-4402.
        doi: 10.1073/pnas.93.9.4398

    13. Ohishi W, Chayama K. 2003. Rare quasispecies in the YMDD motif of hepatitis B virus detected by polymerase chain reaction with peptide nucleic acid clamping. Intervirology, 46: 355-361.
        doi: 10.1159/000074992

    14. Ou Z Y, Liu N, Chen C J, et al. 2005. Rapid and accurate genotyping of YMDD motif variants in the hepatitis B virus genome by an improved reverse dot blot method. J Clin Microbiol, 43: 5685-5689.
        doi: 10.1128/JCM.43.11.5685-5689.2005

    15. Su Q, Fu Y, Liu Y F, et al. 2003. Laminin induces the expression of cytokeratin 19 in hepatocellular carcinoma cells growing in culture. World J Gastroenterol, 9: 921-929.
        doi: 10.3748/wjg.v9.i5.921

    16. Yan J C, Ma J Y, Pan B R, et al. 2001. The study of chronic hepatitis B in China. World Chin J Digestol, 9: 611-616.

    17. Zeuzem S, de Man R A, Honkoop P, et al. 1997. Dynamics of hepatitis B virus infection in vivo. J Hepatol, 27: 431-436.
        doi: 10.1016/S0168-8278(97)80345-5

    18. Zoulim F. 2001. Detection of hepatitis B virus resistance to antivirals. J Clin Virol, 21: 243-253.
        doi: 10.1016/S1386-6532(00)00167-0

  • 加载中

Figures(3) / Tables(3)

Article Metrics

Article views(2709) PDF downloads(3) Cited by()

Related
Proportional views
    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    YVDD Mutation of Hepatitis B Virus, a Dominant Lamivudine-Resistant Type in Guangzhou, South China

      Corresponding author: Yun-shao HE, gzcentralab@yahoo.com.cn
    • 1. Guangzhou Children's Hospital, 318 RenMingZhong Rd, Guangzhou 510120, China
    • 2. Daan Gene Diagnostic Center of Sun Yat-sen University, 74 Zhongshan Rd 2nd, Guangzhou, 510081, China
    Fund Project: 

    Abstract: The epidemiological effects of native and mutated YMDD motif in the HBV genome under the selective pressure of lamivudine were investigated. YMDD wild and mutation motif in HBV genome were detected by flow through reverse dot blots (FT-RDB) with KaiPuTM DNA HybriMax Rapid Hybridization Machine based on the principle of “Flow-through hybridization” and by the traditional Reverse Dot Blot assay. Sera from 1 021 suspected lamivudine-resistant chronic HBV carriers after more than 8 months of lamivudine therapy and the corresponding archived sera were collected and assayed. We found 35.94% were single type infections with 8.03% YMDD, 7.93% YIDD and 19.98% YVDD. It was also found that 64.06% were mixed infections including 1.96% YMDD and YIDD, 51.62% YMDD and YVDD, 1.96% YIDD and YVDD, 8.52% YMDD, YIDD and YVDD. The levels of infections containing YVDD motif reached 82.08%. The pretreatment infectious status were: YMDD single infection was 36.93%; YIDD single infection was 6.07%; YVDD single infection was 17.04%; YMDD and YIDD mixed infection was 0.97%; YMDD and YVDD mixed infection was 33.99%; YIDD and YVDD mixed infection was 0.98%; YMDD, YIDD and YVDD mixed infection was 4.02%. Infections containing YVDD motif were only 56.03%. The 34.32% mutation rate of YMDD motif to YVDD was significantly higher than the 10.97% of YMDD to YIDD (U=10.98, P<0.05), as estimated by Mann-Whitney U-test for non-parametric data. HBV containing YVDD motif might have an evolutionary ascendancy and become the dominant type under the selective pressure of lamivudine.